Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 24 Oct 2017 |
| Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2017 | 17 Oct 2017 |
| Articles of Association for Genmab A/S | 13 Oct 2017 |
| Genmab and Seattle Genetics to Initiate New Study of Novel Antibody-Drug Conjugate Tisotumab Vedotin in Cervical Cancer | 10 Oct 2017 |
| Grant of Restricted Stock Units and Warrants to Genmab employees | 5 Oct 2017 |